Since there are no clinically-available antibodies directly targeting melanoma cells, and half of patients with melanoma do not respond or develop resistance to approved therapies, we sought to develop an ADC based on a novel payload class to which melanoma cells may be susceptible, using an antibody that recognizes a cell surface antigen expressed by a large proportion of melanomas. This evidence concerns the gene CD53 and melanoma.